Skip to content
Pouls MedTech Insights
Anti-VEGF retina injections. Live sample.

Every Medicare anti-VEGF dose, mapped.

Eylea, Lucentis, off-label Avastin, and Eylea HD doses billed to Medicare in the most recent public release. About 5,512,368 doses across roughly 3,543 retina-administering practices nationally. Click any state to see the drug-mix and the practice roster the same way a custom portal would let your team navigate the data we ship.

Buyer note: the figures below capture Medicare Part B fee-for-service only. The multi-payer market (Medicare Advantage, Medicaid, commercial) is materially larger; this view is a directional signal of where prescribers and facilities concentrate, not a market-size claim.

5,512,368 doses billed to Medicare per year
1,512 retina-administering practices
$2.7b visible Medicare anti-VEGF spend Medicare Part B FFS only · multi-payer market materially larger
35.9% share in the top 5 states
National drug mix
  • Eylea
  • Lucentis
  • Avastin (off-label)
  • Eylea HD
On the map

Discover where retina injection volume concentrates.

Click any state for facility-level detail.

Anti-VEGF retina injection volume by US state. Each state is shaded by the number of anti-VEGF retina injections performed there, with darker states indicating higher volume. The top 5 states by volume are California, Florida, Texas, Pennsylvania and New York.

One example. We align the scope to your goals.

Anti-vegf retina injections volume and retina-administering practices counts by US state.
State Doses Retina-administering practices
Alaska 4,542 5
Alabama 64,441 43
Arkansas 36,012 30
Arizona 90,845 51
California 478,938 379
Colorado 77,492 60
Connecticut 60,680 49
District of Columbia 4,297 9
Delaware 11,312 7
Florida 444,692 254
Georgia 124,590 76
Hawaii 10,132 16
Iowa 74,006 40
Idaho 33,118 26
Illinois 225,567 160
Indiana 100,508 67
Kansas 88,355 29
Kentucky 65,536 42
Louisiana 47,570 58
Massachusetts 161,791 94
Maryland 199,003 104
Maine 24,264 21
Michigan 173,318 120
Minnesota 73,769 49
Missouri 102,280 66
Mississippi 99,960 22
Montana 21,844 19
North Carolina 199,881 107
North Dakota 13,380 17
Nebraska 38,793 22
New Hampshire 13,054 12
New Jersey 156,623 96
New Mexico 36,443 20
Nevada 36,466 27
New York 319,776 271
Ohio 123,393 105
Oklahoma 53,659 35
Oregon 68,383 62
Pennsylvania 343,420 150
Rhode Island 17,011 16
South Carolina 144,002 56
South Dakota 18,099 13
Tennessee 192,762 80
Texas 390,102 247
Utah 53,431 40
Virginia 179,875 77
Vermont 7,335 5
Washington 109,112 95
Wisconsin 67,580 78
West Virginia 22,078 8
Wyoming 7,741 2
About this dataset

Methodology & scope.

Source

CMS Medicare Physician & Other Practitioners (most recent public release). Office and outpatient hospital settings combined.

Drugs covered

Eylea, Lucentis, Eylea HD, and Avastin. Avastin is FDA-approved for oncology and used off-label as a low-cost anti-VEGF alternative for retinal disease. This map captures total Medicare administration; retina specialists drive the overwhelming share. A specialty-level filter is available in a custom data engagement.

Scope

Medicare Part B fee-for-service only. Medicare Advantage, Medicaid, and commercial-payer utilization are not included. The full multi-payer market is materially larger than what is shown here.

Want this for your category?

One paragraph about what you're trying to figure out. We'll reply with what we'd ship.

Want this for your category?

Send the question. We turn it into a report, a dashboard, a dataset, or a sample like the one above. Site-licensed by default. No per-seat fees.

Scope a project More live samples